related documents
- M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf Conference Paper
- M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on Conference Paper
- M34 Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the tomorrow and inpulsis trials Conference Paper
- P220 Profiling of occupations and exposures of patients diagnosed with occupational respiratory diseases at a uk regional referral unit Conference Paper